Melphalan Hikma

Melphalan, the active ingredient in Melphalan Hikma, is an alkylating agent presented as an injectable solution for intravenous use. It is employed in the treatment of certain hematologic and solid tumors, including multiple myeloma, ovarian cancer, melanoma and neuroblastoma, in adult patients.

GNH USA supplies Melphalan Hikma as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU quality standards and providing the product to hospitals, oncology centres, transplant units and pharmacies worldwide through regulated distribution channels for cancer therapy and patient care.

Melphalan is an alkylating antineoplastic agent used in the management of several malignancies. - Multiple myeloma: reduces tumor burden and prolongs survival in eligible patients. - Ovarian cancer: improves response rates when combined with other chemotherapeutics. - Melanoma: provides cytoreductive activity in advanced disease. - Neuroblastoma: contributes to disease control in high‑risk pediatric cases.

Melphalan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: frequent gastrointestinal upset that may require anti‑emetic therapy. - Myelosuppression: reduction in white blood cells, red blood cells and platelets leading to anemia, infection risk and bleeding. - Fatigue: persistent tiredness affecting daily activities during and after treatment. - Mucositis: inflammation and ulceration of the oral cavity and gastrointestinal tract causing pain and difficulty eating.

Serious or Rare Side Effects: - Secondary malignancies: potential development of therapy‑related leukemia or other cancers years after exposure. - Severe infection: life‑threatening bacterial or fungal infections due to profound neutropenia. - Pulmonary toxicity: interstitial pneumonitis or fibrosis that may impair breathing. - Cardiotoxicity: rare episodes of cardiac dysfunction, including arrhythmias or reduced ejection fraction.

When using Melphalan, several precautions should be observed to minimize risks. - Pregnancy: contraindicated in pregnancy (Category D) due to fetal toxicity. - Renal impairment: dose adjustment may be required in patients with reduced kidney function. - Hepatic dysfunction: monitor liver enzymes and consider dose modification. - Concomitant myelosuppressive therapy: avoid combining with other agents that further suppress bone marrow. - Monitoring: regular complete blood counts and organ function tests are essential. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Melphalan can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Live vaccines: risk of severe infection; avoid administration during treatment. - Strong CYP inducers: agents such as rifampin may lower melphalan exposure. - High-dose radiation: combined use may increase tissue toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants: enhanced bleeding risk; monitor coagulation parameters. - Nephrotoxic drugs: concurrent use may worsen renal impairment. - Other alkylating agents: additive myelosuppression; adjust dosing as needed.